Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) ...

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...

CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...

ODAC unanimously opposed Talzenna/Xtandi for non-HRR-mutant mCRPC due to increased toxicity and undefined efficacy in non-HRR-mutated patients. UGN-102 for recurrent NMIBC faced a narrow vote against ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair ...